Indian drugmaker faces LCIA claim over covid vaccine

A Seattle biotech company is bringing an LCIA claim against its Indian former business partner amid a US$950 million dispute over alleged theft of technology used to develop covid-19 vaccines.

Get unlimited access to all Global Arbitration Review content